Syndax Pharmaceuticals Inc. has announced new compensation terms under its 2023 Inducement Plan, granting inducement awards to seven new employees. The awards include options to purchase up to 48,600 shares of common stock. The stock options will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the vesting commencement date. Subsequently, 1/48th of the shares will vest monthly over the next 36 months, contingent upon the continuation of the employees' service with the company. This plan aims to align employee interests with the company's long-term success.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。